[go: up one dir, main page]

US20150011772A1 - Method for producing substituted anthranilic acid derivatives - Google Patents

Method for producing substituted anthranilic acid derivatives Download PDF

Info

Publication number
US20150011772A1
US20150011772A1 US14/375,496 US201314375496A US2015011772A1 US 20150011772 A1 US20150011772 A1 US 20150011772A1 US 201314375496 A US201314375496 A US 201314375496A US 2015011772 A1 US2015011772 A1 US 2015011772A1
Authority
US
United States
Prior art keywords
chlorine
alkyl
fluorine
formula
identically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/375,496
Inventor
Thomas Himmler
Sergii Pazenok
Frank Volz
Norbert Lui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Assigned to BAYER INTELLECTUAL PROPERTY GMBH reassignment BAYER INTELLECTUAL PROPERTY GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VOLZ, FRANK, LUI, NORBERT, HIMMLER, THOMAS, PAZENOK, SERGII
Publication of US20150011772A1 publication Critical patent/US20150011772A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/30Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated

Definitions

  • the present invention relates to a novel process for preparing substituted anthranilic acid derivatives of the formula (I)
  • R 1 , R 3 and R 4 radicals are each as defined above and
  • R 6 and R 7 are each as defined above.
  • substituted anthranilic acid derivatives of the formula (I) require the availability of the corresponding substituted anthranilic acid derivatives of the general formula (VII).
  • substituted anthranilic acid derivatives of the general formula (VII) are either known or can be prepared by known organic chemistry methods. Some of these substituted anthranilic acid derivatives of the general formula (VII), however, can be prepared only in a complex manner, in multiple stages and at high cost, which can lead to uneconomically high costs for the end products as a result of unavoidable yield losses.
  • Substituted anthranilic acid derivatives of the formula (I) are of high interest as compounds having known insecticidal efficacy (see, for example, Bioorg. & Med. Chem. Lett. 15 (2005) 4898-4906; Biorg. & Med. Chem. 16 (2008) 3163-3170). Further, it is already known, that substituted anthranilic acid derivatives of the general formula (VII) can be obtained by reacting substituted anthranilic acid derivatives of the general formula (IX) with carbon monoxide in the presence of a palladium catalyst, of a ligand, of a primary amine and a base (WO 2012/103436). However, it is not known whether anthranilic acid amides of the general formula (IV) can be used correspondingly.
  • R 6 and R 7 are each as defined above to give the substituted anthranilic acid derivatives of the general formula (I).
  • the present invention likewise provides novel compounds of the general formula (IV)
  • R 1 , R 3 , R 4 and X radicals are each as defined above.
  • Alkyl groups substituted by one or more fluorine or chlorine atoms are selected, for example, from trifluoromethyl (CF 3 ), difluoromethyl (CHF 2 ), CCl 3 , CFCl 2 , CF 3 CH 2 , ClCH 2 , CF 3 CCl 2 .
  • Alkyl groups in the context of the present invention are linear or branched hydrocarbyl groups.
  • alkyl and C 1 -C 12 -alkyl encompasses, for example, the meanings of methyl, ethyl, n-, isopropyl, n, iso-, sec- and t-butyl, n-pentyl, n-hexyl, 1,3-dimethylbutyl, 3,3-dimethylbutyl, n-heptyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl.
  • Aryl radicals in the context of the present invention are aromatic hydrocarbyl radicals which may have one, two or more heteroatoms selected from O, N, P and S and may optionally be substituted by further groups.
  • Alkylaryl groups (alkaryl groups) and alkylaryloxy groups in the context of the present invention are, respectively, aryl groups and aryloxy groups which are substituted by alkyl groups, may have a C 1-8 -alkylene chain and may have, in the aryl skeleton or aryloxy skeleton, one or more heteroatoms selected from O, N, P and S.
  • Anthranilic acid derivatives of the formula (IV) can be prepared as follows:
  • the reaction time may, according to the batch size and the temperature, be selected within a range between 1 hour and several hours.
  • Process step 1 can optionally be performed in the presence of a catalyst.
  • a catalyst examples include 4-dimethylaminopyridine or 1-hydroxybenzotriazole.
  • the amount of palladium catalyst used in the process according to the invention is 0.001 to 20 mole percent, based on substituted anthranilic acid derivative of the general formula (IV) used. Preferably 0.005 to 10 mole percent is used, more preferably 0.01 to 5 mole percent.
  • phosphine ligands include chelating bisphosphines. Examples of these include 1,2-bis(diphenylphosphino)ethane, 1,2-bis(diphenylphosphino)propane, 1,2-bis(diphenylphosphino)butane, 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl and 1,1′-bis(diphenylpho sphino)ferrocene.
  • Preferred phosphine ligands are trialkylphosphines such as tri-tert-butylphosphine and triadamantylphosphine, and also triarylphosphines such as triphenylphosphine, tri(ortho-tolyl)phosphine or tri(para-methoxyphenyl)phosphine. Particular preference is given to triphenylphosphine.
  • phosphine 1-20 molar equivalents of phosphine are used, based on the amount of palladium used. Preferably 2-15 molar equivalents are used.
  • Process step 2 of the process according to the invention is performed in the presence of carbon monoxide (CO).
  • CO carbon monoxide
  • the carbon monoxide is typically introduced in gaseous form, and so the reaction is usually performed in an autoclave. It is customary to work at CO pressure 0.1 to 50 bar, preferably at 1 to 25 bar.
  • carbon monoxide in the form of suitable metal carbonyl complexes, for example dicobalt octacarbonyl or molybdenum hexacarbonyl. Preference is given to working with gaseous carbon monoxide.
  • Process step 2 is generally performed in the presence of a base.
  • Suitable bases are organic bases such as trialkylamines, alkylpyridines, phosphazenes and 1,8-diazabicyclo[5.4.0]undecene (DBU).
  • organic bases such as triethylamine, tripropylamine, tributylamine, diisopropylethylamine, pyridine, alkylpyridines, for example 2,6-dimethylpyridine, 2-methyl-5-ethylpyridine or 2,3-dimethylpyridine.
  • the compounds of the general formula (V) or (VI) required for preparation of the substituted anthranilic acid derivatives of the general formula (I) are typically used in an excess, based on the substituted anthranilic acid derivative of the general formula (IV). It is also possible to use the compounds of the general formula (V) or (VI) in such an amount that they simultaneously serve as solvents.
  • the autoclave After closure, the autoclave is purged with carbon monoxide and heated to 110° C., and a carbon monoxide pressure of 10 bar is maintained After 18 hours, the mixture is allowed to cool to room temperature, the autoclave is depressurized, the reaction mixture is stirred with methylene chloride and filtered through kieselguhr, and the filtrate is washed, first with dilute hydrochloric acid and then with water, dried over sodium sulphate and concentrated under reduced pressure. This gives 1.14 g of the title compound.
  • the reaction mixture is stirred at room temperature for one hour and at 40° C. for 1 hour and cooled to room temperature, water and methylene chloride are added thereto, and the organic phase is removed, washed with dilute hydrochloric acid, dried and concentrated.
  • the crude product thus obtained is purified by chromatography on silica gel (cyclohexane/ethyl acetate). This gives 1.30 g of the title compound as a pale beige solid.
  • the autoclave After closure, the autoclave is purged with carbon monoxide and heated to 110° C., and a carbon monoxide pressure of 10 bar is maintained. After 18 hours, the mixture is allowed to cool to room temperature, the autoclave is depressurized, the reaction mixture is stirred with methylene chloride and filtered through kieselguhr, and the filtrate is washed, first with dilute hydrochloric acid and then with water, dried over sodium sulphate and concentrated under reduced pressure. This gives 0.49 g of the title compound.
  • the autoclave After closure, the autoclave is purged with carbon monoxide and heated to 110° C., and a carbon monoxide pressure of 10 bar is maintained. After 18 hours, the mixture is allowed to cool to room temperature, the autoclave is depressurized, the reaction mixture is stirred with methylene chloride and filtered through kieselguhr, and the filtrate is washed, first with dilute hydrochloric acid and then with water, dried over sodium sulphate and concentrated under reduced pressure. This gives 0.475 g of the title compound.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to a process for preparing substituted anthranilic acid derivatives of the formula (I)
Figure US20150011772A1-20150108-C00001
in which R1, R2, R3 and R4 are each as defined in the description, by conversion of compounds of the general formula (IV) in the presence of a palladium catalyst and carbon monoxide. The present invention likewise relates to compounds of the general formula (IV).
Figure US20150011772A1-20150108-C00002

Description

  • The present invention relates to a novel process for preparing substituted anthranilic acid derivatives of the formula (I)
  • Figure US20150011772A1-20150108-C00003
  • in which
      • R1 is optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C6-alkyl, or C6-C10-aryl, or is a hetaryl radical of the general formula (II)
  • Figure US20150011772A1-20150108-C00004
      • R1 is preferably C1-C3-alkyl, C6-aryl or a hetaryl radical of the general formula (II),
      • R1 is more preferably C1-C2-alkyl or a hetaryl radical of the general formula (II),
        where
      • R8 is C1-C6-alkyl, C3-C6-cycloalkyl, C1-C4-alkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, which may optionally be mono- or polysubstituted identically or differently by fluorine or chlorine, or is fluorine, chlorine, cyano, alkylamino, dialkylamino, cycloalkylamino or C3-C6-trialkylsilyl,
      • R8 is preferably fluorine, chlorine or C1-C6-alkyl,
      • R8 is more preferably fluorine or chlorine,
      • Z is CH or N,
      • Z is preferably and more preferably N,
        and
      • Y is hydrogen, fluorine, chlorine, optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C6-alkyl, C3-C6-cycloalkyl, C1-C4-alkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, or is cyano, alkylamino, dialkylamino, cycloalkylamino, C3-C6-trialkylsilyl or a radical of the general formula (III)
  • Figure US20150011772A1-20150108-C00005
  • where
      • R9 is C1-C5-alkyl which may optionally be mono- or polysubstituted identically or differently by halogen,
      • R9 is preferably C1-C3 perfluoroalkyl,
      • R9 is more preferably CF3 or C2F5,
      • R2 is an OR5 or NR6R7 radical,
      • R2 is preferably and more preferably OR5,
      • R2 is likewise preferably and more preferably NR6R7,
        where
      • R5, R6 and R7 are each independently hydrogen, C1-C6-alkyl, or C6-C10-aryl,
      • R5, R6 and R7 are preferably each independently hydrogen, C1-C3-alkyl or C6-aryl,
      • R5, R6 and R7 are more preferably each independently hydrogen or C1-C2-alkyl,
      • R3 is hydrogen, optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C6-alkyl, C1-C6-alkoxy or C3-C6-cycloalkyl,
      • R3 is likewise halogen,
      • R3 is preferably C1-C5-alkyl,
      • R3 is more preferably methyl, ethyl or tert-butyl,
      • R3 is likewise preferably and more preferably chlorine,
      • R4 is hydrogen, fluorine, chlorine, cyano, optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C4-alkyl, C1-C4-alkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, C1-C4-alkylamino, di(C1-C4-alkyflamino, C3-C6-cycloalkylamino, (C1-C4-alkoxy)imino, (C1-C4-alkyl)(C1-C4-alkoxy)imino, SF5 or C3-C6-trialkylsilyl,
      • R4 is preferably hydrogen, chlorine or cyano,
      • R4 is more preferably chlorine or cyano,
        characterized in that substituted anthranilic acid derivatives of the formula (IV)
  • Figure US20150011772A1-20150108-C00006
  • in which the R1, R3 and R4 radicals are each as defined above
    and
      • X is chlorine, bromine or iodine, preferably bromine or iodine, more preferably bromine,
        are reacted in the presence of a palladium catalyst and optionally of a phosphine ligand simultaneously with carbon monoxide and a compound of the general formula (V)

  • R5-OH   (V)
  • in which R5 is as defined above
    or a compound of the general formula (VI)

  • HNR6R7   (VI)
  • in which R6 and R7 are each as defined above.
  • The literature already states that it is possible to obtain substituted anthranilic acid derivatives of the formula (I) by reaction of anthranilic acid derivatives of the general formula (VII)
  • Figure US20150011772A1-20150108-C00007
  • with carboxylic acids of the general formula (VIII)

  • R1-COOH   (VIII)
  • in the presence of agents which activate the carboxyl group for the desired reaction, for example thionyl chloride, oxalyl chloride, phosgene, methanesulphonyl chloride or toluenesulphonyl chloride (WO 2003/015519; WO 2003/106427; WO 2004/067528; WO 2006/062978; WO 2008/010897; WO 2008/070158; WO 2008/082502; WO 2009/006061; WO 2009/061991; WO 2009/085816; WO 2009 111553; Bioorg. & Med. Chem. Lett. 15 (2005) 4898-4906; Bioorg. & Med. Chem. 16 (2008) 3163-3170).
  • The known reactions can be illustrated by the following reaction schemes, where R1, R3, R4, R6 and R7 have, for example, the definitions given above:
  • Figure US20150011772A1-20150108-C00008
  • Figure US20150011772A1-20150108-C00009
  • These known methods for preparation of substituted anthranilic acid derivatives of the formula (I) require the availability of the corresponding substituted anthranilic acid derivatives of the general formula (VII). These substituted anthranilic acid derivatives of the general formula (VII) are either known or can be prepared by known organic chemistry methods. Some of these substituted anthranilic acid derivatives of the general formula (VII), however, can be prepared only in a complex manner, in multiple stages and at high cost, which can lead to uneconomically high costs for the end products as a result of unavoidable yield losses.
  • Substituted anthranilic acid derivatives of the formula (I) are of high interest as compounds having known insecticidal efficacy (see, for example, Bioorg. & Med. Chem. Lett. 15 (2005) 4898-4906; Biorg. & Med. Chem. 16 (2008) 3163-3170). Further, it is already known, that substituted anthranilic acid derivatives of the general formula (VII) can be obtained by reacting substituted anthranilic acid derivatives of the general formula (IX) with carbon monoxide in the presence of a palladium catalyst, of a ligand, of a primary amine and a base (WO 2012/103436). However, it is not known whether anthranilic acid amides of the general formula (IV) can be used correspondingly.
  • It is therefore an object of the present invention to provide a novel, more economically viable process for preparing substituted anthranilic acid derivatives of the formula (I).
  • The object was achieved according to the present invention by a process for preparing anthranilic acid derivatives of the general formula (I), characterized in that substituted anthranilic acid derivatives of the general formula (IX)
  • Figure US20150011772A1-20150108-C00010
  • in which X, R3 and R4 are each as defined above
    are reacted with acids of the general formula (VIII) to give the substituted anthranilic acid derivatives of the formula (IV)
  • Figure US20150011772A1-20150108-C00011
  • and the latter are then reacted in the presence of a palladium catalyst and optionally of a phosphine ligand simultaneously with carbon monoxide and a compound of the general formula (V)

  • R5-OH   (V)
  • in which R5 is as defined above
    or a compound of the general formula (VI)

  • HNR6R7   (VI)
  • in which R6 and R7 are each as defined above
    to give the substituted anthranilic acid derivatives of the general formula (I).
  • The process according to the invention can be illustrated by the following scheme:
  • Figure US20150011772A1-20150108-C00012
  • The present invention likewise provides novel compounds of the general formula (IV)
  • Figure US20150011772A1-20150108-C00013
  • in which the R1, R3, R4 and X radicals are each as defined above.
  • Preference is given to compounds of the general formula (IV) in which
      • R1 is optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C6-alkyl, or C6-C10-aryl, or is a hetaryl radical of the general formula (II)
  • Figure US20150011772A1-20150108-C00014
  • where
      • R8 is optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C6-alkyl, C3-C6-cycloalkyl, C1-C4-alkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, or is fluorine, chlorine, cyano, alkylamino, dialkylamino, cycloalkylamino or C3-C6-trialkylsilyl, preferably fluorine, chlorine or C1-C6-alkyl, more preferably fluorine or chlorine,
      • Z is CH or N, preferably N,
        and
      • Y is hydrogen, fluorine, chlorine, optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C6-alkyl, C3-C6-cycloalkyl, C1-C4-alkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, or is cyano, alkylamino, dialkylamino, cycloalkylamino, C3-C6-trialkylsilyl or a radical of the general formula (III)
  • Figure US20150011772A1-20150108-C00015
  • in which
      • R9 is C1-C5-alkyl which may be mono- or polysubstituted identically or differently by halogen,
      • R9 is preferably C1-C3-perfluoroalkyl,
      • R9 is more preferably CF3 or C2F5,
      • R3 is chlorine,
      • R3 is likewise methyl,
      • R4 is chlorine or cyano,
        and
      • X is bromine or iodine.
  • Particular preference is given to compounds of the general formula (IV) in which
      • R1 is a hetaryl radical of the general formula (II)
  • Figure US20150011772A1-20150108-C00016
  • where
      • R8 is fluorine or chlorine,
      • Z is N,
        and
      • Y is hydrogen, fluorine, chlorine or a radical of the general formula (III)
  • Figure US20150011772A1-20150108-C00017
  • where
      • R9 is CF3 or C2F5,
      • R3 is methyl,
      • R4 is chlorine or cyano,
        and
      • X is bromine
  • Examples of the particularly preferred compounds of the general formula (IV) include:
  • N-(2-bromo-4-cyano-6-methylphenyl)-1-(3-chloropyridin-2-yl)-3-{[5-(trifluoromethyl)-2H-tetrazol-2-yl]methyl}-1H-pyrazole-5-carboxamide
  • N-(2-bromo-4-chloro-6-methylphenyl)-1-(3-chloropyridin-2-yl)-3-{[5-(pentafluoroethyl)-2H-tetrazol-2-yl]methyl}-1H-pyrazole-5-carboxamide.
  • General definitions: Alkyl groups substituted by one or more fluorine or chlorine atoms (=fluoro- or chloroalkyl groups) are selected, for example, from trifluoromethyl (CF3), difluoromethyl (CHF2), CCl3, CFCl2, CF3CH2, ClCH2, CF3CCl2.
  • Alkyl groups in the context of the present invention, unless defined differently, are linear or branched hydrocarbyl groups.
  • The definition alkyl and C1-C12-alkyl encompasses, for example, the meanings of methyl, ethyl, n-, isopropyl, n, iso-, sec- and t-butyl, n-pentyl, n-hexyl, 1,3-dimethylbutyl, 3,3-dimethylbutyl, n-heptyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl.
  • Cycloalkyl groups in the context of the present invention, unless defined differently, are cyclic saturated hydrocarbyl groups.
  • Aryl radicals in the context of the present invention, unless defined differently, are aromatic hydrocarbyl radicals which may have one, two or more heteroatoms selected from O, N, P and S and may optionally be substituted by further groups.
  • Arylalkyl groups and arylalkoxy groups in the context of the present invention, unless defined differently, are, respectively, alkyl and alkoxy groups which are substituted by aryl groups and may have an alkylene chain. Specifically, the definition arylalkyl encompasses, for example, the meanings of benzyl and phenylethyl, and the definition arylalkoxy, for example, the meaning of benzyloxy.
  • Alkylaryl groups (alkaryl groups) and alkylaryloxy groups in the context of the present invention, unless defined differently, are, respectively, aryl groups and aryloxy groups which are substituted by alkyl groups, may have a C1-8-alkylene chain and may have, in the aryl skeleton or aryloxy skeleton, one or more heteroatoms selected from O, N, P and S.
  • Step 1
  • Anthranilic acid derivatives of the formula (IV) can be prepared as follows:
  • Figure US20150011772A1-20150108-C00018
  • The reaction is performed in the presence of a condensing agent. Suitable agents for this purpose are all agents customary for such coupling reactions. Examples include acid halide formers such as phosgene, phosphorus tribromide, phosphorus trichloride, phosphorus pentachloride, phosphorus oxychloride, oxalyl chloride or thionyl chloride; anhydride formers such as ethyl chloroformate, methyl chloroformate, isopropyl chloroformate, isobutyl chloroformate or methanesulphonyl chloride; carbodiimides such as N,N′-dicyclohexylcarbodiimide (DCC) or other customary condensing agents such as phosphorus pentoxide, polyphosphoric acid, 1,1′-carbonyldiimidazole, 2-ethoxy-N-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ), triphenylphosphine/carbon tetrachloride, bromotripyrrolidinophosphonium hexafluorophosphate, bis(2-oxo-3-oxazolidinyl)phosphine chloride or benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate. It is likewise possible to use polymer-supported reagents, for example polymer-bound cyclohexylcarbodiimide
  • Preference is given to phosgene, mesyl chloride and thionyl chloride.
  • Process step 1 can optionally be performed in the presence of an inert organic diluent customary for such reactions. These preferably include aliphatic, alicyclic or aromatic hydrocarbons, for example petroleum ether, hexane, heptane, cyclohexane, methylcyclohexane, benzene, toluene, xylene or decalin; halogenated hydrocarbons, for example chlorobenzene, dichlorobenzene, dichloromethane, chloroform, carbon tetrachloride, dichloroethane or trichloroethane; ethers such as diethyl ether, diisopropyl ether, methyl tert-butyl ether, methyl tert-amyl ether, dioxane, tetrahydrofuran, 1,2-dimethoxyethane, 1,2-diethoxyethane or anisole; ketones such as acetone, butanone, methyl isobutyl ketone or cyclohexanone; nitriles such as acetonitrile, propionitrile, n- or isobutyronitrile or benzonitrile; amides such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylformanilide, N-methylpyrrolidone or hexamethylphosphoramide, or mixtures thereof.
  • Process step 1 is generally performed in the presence of a base.
  • Suitable bases are alkali metal hydroxides, for example lithium hydroxide, sodium hydroxide or potassium hydroxide, alkali metal carbonates, for example Na2CO3, K2CO3, and acetates, for example NaOAc, KOAc, LiOAc, and also alkoxides, for example NaOMe, NaOEt, NaOt-Bu, KOt-Bu. Likewise suitable bases are organic bases such as trialkylamines, alkylpyridines, phosphazenes and 1,8-diazabicyclo[5.4.0]undecene (DBU). Preference is given to organic bases such as pyridines, alkylpyridines, for example 2,6-dimethylpyridine, 2-methyl-5-ethylpyridine or 2,3-dimethylpyridine.
  • Process step 1 of the invention is performed preferably within a temperature range from 20° C. to +100° C., more preferably at temperatures of 30° C. to +80 ° C., more preferably at 30-60° C.
  • Process step 1 of the invention is generally performed under standard pressure. Alternatively, however, it is also possible to work under vacuum or under elevated pressure in an autoclave.
  • The reaction time may, according to the batch size and the temperature, be selected within a range between 1 hour and several hours.
  • Process step 1 can optionally be performed in the presence of a catalyst. Examples include 4-dimethylaminopyridine or 1-hydroxybenzotriazole.
  • Step 2
  • Substituted anthranilic acid derivatives of the general formula (1) can be prepared in accordance with process step 2 as follows:
  • Figure US20150011772A1-20150108-C00019
  • The reaction is performed in the presence of a palladium catalyst. The palladium catalysts used in the process according to the invention are palladium(II) salts, for instance palladium chloride, bromide, iodide, acetate or acetylacetonate, which may optionally be stabilized by further ligands, for example alkyl nitriles, or Pd(O) species, for example palladium on activated carbon, Pd(PPh3)4, bis(dibenzylideneacetone)palladium or tris(dibenzylideneacetone)dipalladium. Preference is given to bis(dibenzylideneacetone)palladium, tris(dibenzylideneacetone)dipalladium, palladium chloride, palladium bromide and palladium acetate; particular preference is given to bis(dibenzylideneacetone)palladium, palladium chloride and palladium acetate.
  • The amount of palladium catalyst used in the process according to the invention is 0.001 to 20 mole percent, based on substituted anthranilic acid derivative of the general formula (IV) used. Preferably 0.005 to 10 mole percent is used, more preferably 0.01 to 5 mole percent.
  • The phosphine ligands used in the process according to the invention are ligands of the general formula (X)

  • PR10R11R12   (X)
  • where the R10, R11 and R12 radicals are each independently hydrogen, linear or branched C1-C8-alkyl, vinyl, aryl or heteroaryl from the group of pyridine, pyrimidine, pyrrole, thiophene and furan, which may in turn be substituted by further substituents from the group of linear or branched C1-C8-alkyl or C6-C10-aryl, linear or branched C1-C8-alkyloxy or C1-C10-aryloxy, halogenated linear or branched C1-C8-alkyl or halogenated C6-C10-aryl, C6-C10 -aryloxycarbonyl, linear or branched C1-C8-alkylamino, linear or branched C1-C8-dialkylamino, C1-C8-arylamino, C1-C8-diarylamino, hydroxyl, carboxyl, cyano and halogen such as fluorine or chlorine.
  • Further useful phosphine ligands include chelating bisphosphines. Examples of these include 1,2-bis(diphenylphosphino)ethane, 1,2-bis(diphenylphosphino)propane, 1,2-bis(diphenylphosphino)butane, 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl and 1,1′-bis(diphenylpho sphino)ferrocene.
  • Preferred phosphine ligands are trialkylphosphines such as tri-tert-butylphosphine and triadamantylphosphine, and also triarylphosphines such as triphenylphosphine, tri(ortho-tolyl)phosphine or tri(para-methoxyphenyl)phosphine. Particular preference is given to triphenylphosphine.
  • As an alternative to this, it is also possible to use defined palladium complexes which have been obtained from the abovementioned ligands in one or more process steps.
  • In the process according to the invention, 1-20 molar equivalents of phosphine are used, based on the amount of palladium used. Preferably 2-15 molar equivalents are used.
  • Process step 2 of the process according to the invention is performed in the presence of carbon monoxide (CO). The carbon monoxide is typically introduced in gaseous form, and so the reaction is usually performed in an autoclave. It is customary to work at CO pressure 0.1 to 50 bar, preferably at 1 to 25 bar.
  • It is alternatively also possible in principle to introduce the carbon monoxide in the form of suitable metal carbonyl complexes, for example dicobalt octacarbonyl or molybdenum hexacarbonyl. Preference is given to working with gaseous carbon monoxide.
  • Process step 2 is generally performed in the presence of a base. Suitable bases are organic bases such as trialkylamines, alkylpyridines, phosphazenes and 1,8-diazabicyclo[5.4.0]undecene (DBU). Preference is given to organic bases such as triethylamine, tripropylamine, tributylamine, diisopropylethylamine, pyridine, alkylpyridines, for example 2,6-dimethylpyridine, 2-methyl-5-ethylpyridine or 2,3-dimethylpyridine.
  • The compounds of the general formula (V) or (VI) required for preparation of the substituted anthranilic acid derivatives of the general formula (I) are typically used in an excess, based on the substituted anthranilic acid derivative of the general formula (IV). It is also possible to use the compounds of the general formula (V) or (VI) in such an amount that they simultaneously serve as solvents.
  • PREPARATION EXAMPLES
  • The Preparation Examples which follow illustrate the invention without limiting it.
  • Example 1 2-Acetamido-5-cyano-3-methylbenzoic Acid
  • Figure US20150011772A1-20150108-C00020
  • In a 30 ml autoclave, under nitrogen as protective gas, 2.54 g [10 mmol] of N-(2-bromo-4-cyan-6-methylphenyl)acetamide, 3.89 g [21 mmol] of tri-n-butylamine, 0.131 g [0.5 mmol] of triphenylphosphine, 0.035 g [0.05 mmol] of bis(triphenylphosphine)palladium(II) chloride and 2 g of water are combined. After closure, the autoclave is purged with carbon monoxide and heated to 110° C., and a carbon monoxide pressure of 10 bar is maintained After 18 hours, the mixture is allowed to cool to room temperature, the autoclave is depressurized, the reaction mixture is stirred with methylene chloride and filtered through kieselguhr, and the filtrate is washed, first with dilute hydrochloric acid and then with water, dried over sodium sulphate and concentrated under reduced pressure. This gives 1.14 g of the title compound.
  • LC/MS: m/e=219 (MH+).
  • GC/MS(sil.): m/e=362 (M+, 2×sil., 10%), 347 (M+−15, 2×sil., 45%).
  • Example 2 N-(2-Bromo-4-cyano-6-methylphenyl)-1-(3-chloropyridin-2-yl)-3-{[5-(trifluoromethyl)-2H-tetrazol-2-yl]methyl}-1H-pyrazole-5-carboxamide
  • Figure US20150011772A1-20150108-C00021
  • To a solution of 3.74 g of 1-(3-chloropyridin-2-yl)-3-{[5-(trifluoromethyl)-2H-tetrazol-2-yl]methyl}-1H-pyrazole-5-carboxylic acid in 20 ml of acetonitrile are added 1.86 g of 3-methylpyridine. Then 1.37 g of methanesulphonyl chloride are added dropwise at 0° C. After 30 minutes at 0° C., the red solution thus obtained is slowly added dropwise to a solution of 2.11 g of 4-amino-3-bromo-5-methylbenzonitrile and 1.12 g of 3-methylpyridine in 20 ml of acetonitrile. The reaction mixture is stirred at room temperature for one hour and at 40° C. for 1 hour and cooled to room temperature, water and methylene chloride are added thereto, and the organic phase is removed, washed with dilute hydrochloric acid, dried and concentrated. The crude product thus obtained is purified by chromatography on silica gel (cyclohexane/ethyl acetate). This gives 1.30 g of the title compound as a pale beige solid.
  • LC/MS: m/e=566 (MH+ with 79Br and 35Cl).
  • Example 3 Methyl 2-({[1-chloropyridin-2-yl)-3-{[5-(trifluoromethyl)-2H-tetrazol-2-yl]methyl}-1H-pyrazol-5-yl]carbonyl}amino)-5-cyano-3-methylbenzoate
  • Figure US20150011772A1-20150108-C00022
  • In a 30 ml autoclave, under nitrogen as protective gas, 0.567 g of N-(2-bromo-4-cyano-6-methylphenyl)-1-(3-chloropyridin-2-yl)-3-{[5-(trifluoromethyl)-2H-tetrazol-2-yl] methyl}-1H-pyrazole-5-carboxamide, 0.463 g of tri-n-butylamine, 0.066 g of triphenylphosphine, 0.035 g of bis(triphenylphosphine)palladium(II) chloride and 10 ml of methanol are combined. After closure, the autoclave is purged with carbon monoxide and heated to 110° C., and a carbon monoxide pressure of 10 bar is maintained. After 18 hours, the mixture is allowed to cool to room temperature, the autoclave is depressurized, the reaction mixture is stirred with methylene chloride and filtered through kieselguhr, and the filtrate is washed, first with dilute hydrochloric acid and then with water, dried over sodium sulphate and concentrated under reduced pressure. This gives 0.49 g of the title compound.
  • LC/MS: m/e=546 (MH+ with 35Cl).
  • Example 4 1-(3-Chloropyridin-2-yl)-N-[4-cyano-2-(dimethylcarbamoyl)-6-methylphenyl]-3-{[5-(trifluoromethyl)-2H-tetrazol-2-yl]methyl}-1H-pyrazole-5-carboxamide
  • Figure US20150011772A1-20150108-C00023
  • In a 30 ml autoclave, under nitrogen as protective gas, 0.567 g of N-(2-bromo-4-cyano-6-methylphenyl)-1-(3-chloropyridin-2-yl)-3-{[5-(trifluoromethyl)-2H-tetrazol-2-yl]methyl}-1H-pyrazole-5-carboxamide, 0.463 g of tri-n-butylamine, 0.066 g of triphenylphosphine, 0.035 g of bis(triphenylphosphine)palladium(II) chloride and 2 ml of dimethylamine are combined. After closure, the autoclave is purged with carbon monoxide and heated to 110° C., and a carbon monoxide pressure of 10 bar is maintained. After 18 hours, the mixture is allowed to cool to room temperature, the autoclave is depressurized, the reaction mixture is stirred with methylene chloride and filtered through kieselguhr, and the filtrate is washed, first with dilute hydrochloric acid and then with water, dried over sodium sulphate and concentrated under reduced pressure. This gives 0.475 g of the title compound.
  • LC/MS: m/e=559 (MH+ with 35Cl).

Claims (12)

1. Process for preparing a compound of formula (I)
Figure US20150011772A1-20150108-C00024
in which
R1 is optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C6-alkyl, or C6-C10-aryl, or is a hetaryl radical of formula (II)
Figure US20150011772A1-20150108-C00025
where
R8 is C1-C6-alkyl, C3-C6-cycloalkyl, C1-C4-alkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, which may optionally be mono- or polysubstituted, identically or differently by fluorine or chlorine, or is fluorine, chlorine, cyano, alkylamino, dialkylamino, cycloalkylamino or C3-C6-trialkylsilyl,
Z is CH or N,
and
Y is hydrogen, fluorine, chlorine, optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C6-alkyl, C3-C6-cycloalkyl, C1-C4-alkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, or is cyano, alkylamino, dialkylamino, cycloalkylamino, C3-C6-trialkylsilyl or a radical of formula (III)
Figure US20150011772A1-20150108-C00026
where
R9 is C1-C5-alkyl which may optionally be mono- or polysubstituted identically or differently by halogen,
R2 is an OR5 or NR6R7 radical,
where
R5, R6 and R7 are each independently hydrogen, C1-C6-alkyl, or C6-C10-aryl,
R3 is hydrogen, optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C6-alkyl, C1-C6-alkoxy or C3-C6-cycloalkyl,
R4 is hydrogen, fluorine, chlorine, cyano, optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C4-alkyl, C1-C4-alkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C3-C6-cycloalkylamino, (C1-C4-alkoxy)imino, (C1-C4-alkyl)(C1-C4-alkoxy)imino, SF5 or C3-C6-trialkylsilyl,
comprising reacting a substituted anthranilamide derivative of the formula (IV)
Figure US20150011772A1-20150108-C00027
in which the R1, R3 and R4 radicals are each as defined above
and X is chlorine, bromine or iodine,
in the presence of a palladium catalyst and optionally of a phosphine ligand simultaneously with carbon monoxide and a compound of formula (V)

R5—OH   (V)
in which R5 is as defined above
or a compound of formula (VI)

HNR6R7   (VI)
in which R6 and R7 are each as defined above.
2. Process according to claim 1, wherein the compound of formula (IV) is prepared by reacting a Compound of formula (IX)
Figure US20150011772A1-20150108-C00028
in which X, R3 and R4 are each as defined above
with acids of formula (VIII)

R1COOH   (VIII)
in which R1 is as defined above.
3. Process according to claim 2, wherein the compound of formula (IV) is prepared in the presence of a condensing agent and of a base.
4. Process according to claim 1, wherein the palladium catalyst used is a palladium (II) salt and/or Pd(O) species.
5. Process according to claim 4, wherein the palladium catalyst used is bis(dibenzylideneacetone)palladium, tris(dibenzylideneacetone)dipalladium, palladium chloride, palladium bromide and/or palladium acetate.
6. Process according to claim 1, wherein the phosphine ligand used is a compound of formula (X)

PR10R11R12   (X)
where the R10, R11 and R12 radicals are each independently hydrogen, linear or branched C1-C8-alkyl, vinyl, aryl or heteroaryl selected from pyridine, pyrimidine, pyrrole, thiophene and furan, which may in turn be substituted by further substituents from the group of linear or branched C1-C8-alkyl or C6-C10-aryl, linear or branched C1-C8-alkyloxy or C1-C10-aryloxy, halogenated linear or branched C1-C8-alkyl or halogenated C6-C10-aryl, C6-C10-aryloxycarbonyl, linear or branched C1-C8-alkylamino, linear or branched C1-C8-dialkylamino, C1-C8-arylamino, C1-C8-diarylamino, hydroxyl, carboxyl, cyano and halogen,
or a chelating biphosphine.
7. Process according to claim 6, wherein the chelating biphosphine is one or more selected from 1,2-bis(diphenylphosphino)ethane, 1,2-bis(diphenylphosphino)propane, 1,2-bis(diphenylphosphino)butane, 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl and 1,1′-bis(diphenylphosphino)ferrocene.
8. Process according to claim 6, wherein the phosphine ligand used is triphenylphosphine.
9. Process according to claim 6, wherein 1-20 molar equivalents of phosphine are used, based on the amount of palladium catalyst used.
10. Compound of formula (IV)
Figure US20150011772A1-20150108-C00029
Where
R1 is optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C6-alkyl, or C6-C10-aryl, or is a hetaryl radical of formula (II)
Figure US20150011772A1-20150108-C00030
where
R8 is C1-C6-alkyl, C3-C6-cycloalkyl, C1-C4-alkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, which may optionally be mono- or polysubstituted, identically or differently by fluorine or chlorine, or is fluorine, chlorine, cyano, alkylamino, dialkylamino, cycloalkylamino or C3-C6-trialkylsilyl,
Z is CH or N,
and
Y is hydrogen, fluorine, chlorine, optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C6-alkyl, C3-C6-cycloalkyl, C1-C4-alkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, or is cyano, alkylamino, dialkylamino, cycloalkylamino, C3-C6-trialkylsilyl or a radical of formula (III)
Figure US20150011772A1-20150108-C00031
where
R9 is C1-C5-alkyl which may optionally be mono- or polysubstituted identically or differently by halogen,
R2 is an OR5 or NR6R7 radical,
where
R5, R6 and R7 are each independently hydrogen, C1-C6-alkyl, or C6-C10-aryl,
R3 is hydrogen, optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C6-alkyl, C1-C6-alkoxy or C3-C6-cycloalkyl,
R4 is hydrogen, fluorine, chlorine, cyano, optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C4-alkyl, C1-C4-alkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C3-C6-cycloalkylamino, (C1-C4-alkoxy)imino, (C1-C4-alkyl)(C1-C4-alkoxy)imino, SF5 or C3-C6-trialkylsilyl.
11. Compound of formula (IV) according to claim 10, where
R1 is optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C6-alkyl, or C6-C10-aryl, or is a hetaryl radical of the general formula (II)
Figure US20150011772A1-20150108-C00032
where
R8 is optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C6-alkyl, C3-C6-cycloalkyl, C1-C4-alkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, or is fluorine, chlorine, cyano, alkylamino, dialkylamino, cycloalkylamino or C3-C6-trialkylsilyl,
Z is CH or N, and
Y is hydrogen, fluorine, chlorine, C1-C6-alkyl, C3-C6-cycloalkyl, C1-C6-fluoro- or -chloroalkyl, C1-C6-fluoro- or -chlorocycloalkyl, C1-C4-alkoxy, C1-C4-fluoro- or -chloroalkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, C1-C4-fluoro- or -chloroalkylthio, C1-C4-fluoro- or -chloroalkylsulphinyl, C1-C4-fluoro- or -chloroalkylsulphonyl, cyano, alkylamino, dialkylamino, cycloalkylamino, C3-C6-trialkylsilyl or a radical of the general formula (III)
Figure US20150011772A1-20150108-C00033
in which
R9 is C1-C5-alkyl which may be mono- or polysubstituted identically or differently by halogen,
R3 is methyl,
R3 is likewise chlorine,
R4 is chlorine or cyano,
and
X is bromine or iodine.
12. Compound of formula (IV) according to claim 10, where
R1 is a hetaryl radical of the general formula (II)
Figure US20150011772A1-20150108-C00034
where
R8 is fluorine or chlorine,
Z is N,
and
Y is hydrogen, fluorine, chlorine or a radical of the general formula (III)
Figure US20150011772A1-20150108-C00035
where
R9 is CF3 or C2F5,
R3 is methyl,
R4 is chlorine or cyano,
and
X is bromine.
US14/375,496 2012-02-07 2013-02-06 Method for producing substituted anthranilic acid derivatives Abandoned US20150011772A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12154290.6 2012-02-07
EP12154290 2012-02-07
PCT/EP2013/052350 WO2013117601A1 (en) 2012-02-07 2013-02-06 Method for producing substituted anthranilic acid derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/052350 A-371-Of-International WO2013117601A1 (en) 2012-02-07 2013-02-06 Method for producing substituted anthranilic acid derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/924,889 Continuation US9670182B2 (en) 2012-02-07 2015-10-28 Method for producing substituted anthranilic acid derivatives

Publications (1)

Publication Number Publication Date
US20150011772A1 true US20150011772A1 (en) 2015-01-08

Family

ID=47722253

Family Applications (3)

Application Number Title Priority Date Filing Date
US14/375,496 Abandoned US20150011772A1 (en) 2012-02-07 2013-02-06 Method for producing substituted anthranilic acid derivatives
US14/924,889 Expired - Fee Related US9670182B2 (en) 2012-02-07 2015-10-28 Method for producing substituted anthranilic acid derivatives
US15/493,087 Expired - Fee Related US9969717B2 (en) 2012-02-07 2017-04-20 Method for producing substituted anthranilic acid derivatives

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/924,889 Expired - Fee Related US9670182B2 (en) 2012-02-07 2015-10-28 Method for producing substituted anthranilic acid derivatives
US15/493,087 Expired - Fee Related US9969717B2 (en) 2012-02-07 2017-04-20 Method for producing substituted anthranilic acid derivatives

Country Status (10)

Country Link
US (3) US20150011772A1 (en)
EP (1) EP2812310A1 (en)
JP (2) JP2015511229A (en)
KR (1) KR102032979B1 (en)
CN (2) CN104245666B (en)
BR (1) BR112014019487A2 (en)
IL (1) IL233945A0 (en)
MX (1) MX363730B (en)
TW (1) TWI644888B (en)
WO (1) WO2013117601A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150011772A1 (en) * 2012-02-07 2015-01-08 Bayer Intellectual Property Gmbh Method for producing substituted anthranilic acid derivatives
WO2015162260A1 (en) * 2014-04-25 2015-10-29 Basf Se Process for preparing anthranilamide esters and derivatives
CN104961644B (en) * 2015-05-20 2017-04-12 上海交通大学 Method used for preparing N-aryl amide compound
CN106045870B (en) * 2016-07-07 2018-07-03 上海应用技术学院 A kind of method for preparing amide
CN109180518B (en) * 2018-10-18 2021-05-18 陕西科技大学 A kind of secondary/tertiary amide compound and its synthesis method
EP4214188A1 (en) 2020-09-17 2023-07-26 PI Industries Ltd. A process for the synthesis of anthranilic acid/amide compounds and intermediates thereof
CN116535388B (en) * 2023-03-27 2024-12-10 江苏七洲绿色科技研究院有限公司 A kind of preparation method of chlorantraniliprole
WO2025134143A1 (en) 2023-12-19 2025-06-26 Pi Industries Ltd. A method for the synthesis of substituted anthranilic amide compounds, intermediates and salts thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635657B1 (en) * 1998-12-23 2003-10-21 Eli Lilly And Company Aromatic amides
US7456169B2 (en) * 2003-02-27 2008-11-25 Abbott Laboratories Inc. Heterocyclic kinase inhibitors
US7491718B2 (en) * 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3161456D1 (en) * 1980-02-06 1983-12-29 Hoffmann La Roche Process for the preparation of anthranilic acid derivatives
US5739330A (en) * 1996-02-05 1998-04-14 Hoechst Celanese Corporation Process for preparing quinazolones
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
KR20040034594A (en) * 2001-01-26 2004-04-28 브리스톨-마이어스스퀴브컴파니 Imidazolyl Derivatives as Corticotropin Releasing Factor Inhibitors
AR036872A1 (en) 2001-08-13 2004-10-13 Du Pont ANTRANILAMIDE COMPOSITE, COMPOSITION THAT INCLUDES IT AND METHOD FOR CONTROLLING AN INVERTEBRATE PEST
JP2004004374A (en) 2002-05-31 2004-01-08 Canon Inc Flash photographing device
BR0311707A (en) * 2002-06-13 2005-03-15 Du Pont Compound, composition and method of control of at least one invertebrate pest
JP2004043474A (en) * 2002-07-05 2004-02-12 Nippon Nohyaku Co Ltd 2-aminobenzoic acid derivative and method for producing the same
US20040068012A1 (en) * 2002-10-08 2004-04-08 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
EP1599463B1 (en) 2003-01-28 2013-06-05 E.I. Du Pont De Nemours And Company Cyano anthranilamide insecticides
TWI363756B (en) 2004-12-07 2012-05-11 Du Pont Method for preparing n-phenylpyrazole-1-carboxamides
DE102006032168A1 (en) * 2006-06-13 2007-12-20 Bayer Cropscience Ag Anthranilic acid diamide derivatives with heteroaromatic substituents
UA99257C2 (en) * 2006-07-19 2012-08-10 Е.І. Дю Пон Де Немур Енд Компані Process for making 3-substituted 2-amino-5-halobenzamides
TWI395728B (en) 2006-12-06 2013-05-11 Du Pont Process for preparing 2-amino-5-cyanobenzoic acid derivatives
TWI415827B (en) 2006-12-21 2013-11-21 Du Pont Process for preparing 2-amino-5-cyanobenzoic acid derivatives
TWI430980B (en) 2007-06-29 2014-03-21 Du Pont Process for preparing 2-amino-5-cyanobenzoic acid derivatives
KR20100098382A (en) 2007-11-08 2010-09-06 이 아이 듀폰 디 네모아 앤드 캄파니 Process for preparing 2-amino-5-cyanobenzoic acid derivatives
TWI432421B (en) 2007-12-19 2014-04-01 Du Pont Process for preparing 2-amino-5-cyanobenzoic acid derivatives
TWI431000B (en) 2008-03-05 2014-03-21 Du Pont Process for preparing 2-amino-5-cyanobenzoic acid derivatives
KR20160148046A (en) * 2008-12-18 2016-12-23 바이엘 인텔렉쳐 프로퍼티 게엠베하 Tetrazole substituted anthranilic amides as pesticides
BR112012019973B1 (en) * 2010-02-09 2019-02-05 Bayer Cropscience Ag HYDRAZINE-SUBSTITUTED ANTRANYLIC ACID DERIVATIVES, MIXTURES, PRECURSOR COMPOUNDS, AGRICULTURAL COMPOSITIONS, PROCESSES FOR PREPARING THESE COMPOUNDS AND COMPOSITIONS, USE OF THE COMPOUNDS, MIXTURES OR COMPOSITIONS FOR THE MATERIALS AND CONTROLS
ES2554903T3 (en) * 2010-06-15 2015-12-28 Bayer Intellectual Property Gmbh Diaramide derivatives of anthranilic acid with cyclic side chains
MX347841B (en) * 2010-06-15 2017-05-16 Bayer Ip Gmbh Process for preparing tetrazole-substituted anthranilamide derivatives and novel crystal polymorph of these derivatives.
BR112012032259A2 (en) * 2010-06-15 2015-09-15 Bayer Ip Gmbh "New ortho-substituted arylamide derivatives".
KR20140006007A (en) * 2011-01-28 2014-01-15 이 아이 듀폰 디 네모아 앤드 캄파니 Method for preparing 2-aminobenzamide derivatives
US20150011772A1 (en) * 2012-02-07 2015-01-08 Bayer Intellectual Property Gmbh Method for producing substituted anthranilic acid derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635657B1 (en) * 1998-12-23 2003-10-21 Eli Lilly And Company Aromatic amides
US7491718B2 (en) * 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
US7456169B2 (en) * 2003-02-27 2008-11-25 Abbott Laboratories Inc. Heterocyclic kinase inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Fulford, e-EROS Encyclopedia of Reagents for Organic Synthesis (2001), John Wiley &Sons, Chichester, UK) CODEN:69KUHI *
Seo et al. J. Org. Chem. 2006, 71, 8891-8900 *
Sorgi et al. Encyclopedia of Reagents for Organic Synthesis, 2001, doi:10.1002/047084289X.rt164. *
Valentine et al. Journal of Organic Chemistry, 1981, 46, 4614-4617. *

Also Published As

Publication number Publication date
US9670182B2 (en) 2017-06-06
US20170217934A1 (en) 2017-08-03
MX2014009317A (en) 2014-11-12
US9969717B2 (en) 2018-05-15
CN109970707A (en) 2019-07-05
IL233945A0 (en) 2014-09-30
US20160046607A1 (en) 2016-02-18
TWI644888B (en) 2018-12-21
MX363730B (en) 2019-04-01
JP2015511229A (en) 2015-04-16
TW201336811A (en) 2013-09-16
WO2013117601A1 (en) 2013-08-15
EP2812310A1 (en) 2014-12-17
BR112014019487A2 (en) 2020-10-27
KR20140124810A (en) 2014-10-27
KR102032979B1 (en) 2019-10-16
CN104245666B (en) 2019-01-11
JP2018027964A (en) 2018-02-22
JP6438551B2 (en) 2018-12-12
CN104245666A (en) 2014-12-24

Similar Documents

Publication Publication Date Title
US9969717B2 (en) Method for producing substituted anthranilic acid derivatives
US20110003999A1 (en) Process for Preparing Substituted Biphenylanilides
JP5970065B2 (en) Method for producing tetrazole-substituted anthranilic acid diamide derivatives by reacting pyrazolic acid with anthranilic acid ester
KR101949551B1 (en) Method for producing tetrazole-substituted anthranilic acid diamide derivatives by reacting benzoxazinones with amines
KR102167814B1 (en) Method for producing carboxamides
KR101652360B1 (en) Process for preparing substituted biphenyl anilides
JP5140776B1 (en) Process for producing 1-substituted-3-fluoroalkylpyrazole-4-carboxylic acid ester
US9458091B2 (en) Aromatic amidecarboxylic acid and process for producing the same
US9481650B2 (en) Process for the preparation of 2-trifluoromethyl isonicotinic acid and esters

Legal Events

Date Code Title Description
AS Assignment

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HIMMLER, THOMAS;PAZENOK, SERGII;VOLZ, FRANK;AND OTHERS;SIGNING DATES FROM 20140721 TO 20140725;REEL/FRAME:033476/0149

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION